Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis. Fraser WD, Logue FC, Christie JP, Gallacher SJ, Cameron D, O'Reilly DS, Beastall GH, Boyle IT. Osteoporos Int. 1998;8(2):121-6.

Parathyroid hormone pulsatility: physiological and clinical aspects. Chiavistelli S, Giustina A, Mazziotti G. Bone Res. 2015 Jan 27;3:14049.

Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H. Calcif Tissue Int. 2010 Dec;87(6):485-92.

The use of parathyroid hormone in the treatment of osteoporosis. Girotra M, Rubin MR, Bilezikian JP. Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21.

Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler GB Jr. J Clin Endocrinol Metab. 2012 Feb;97(2):391-9.

Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr. J Clin Endocrinol Metab. 2008 Sep;93(9):3389-95.

PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK. J Bone Miner Res. 2009 May;24(5):964-73.

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. J Bone Miner Res. 2012 Dec;27(12):2429-37.